Akihiro Nui
Sapporo Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akihiro Nui.
Transplantation | 2002
Makoto Meguro; Tadashi Katsuramaki; Minoru Nagayama; Hitoshi Kimura; Masato Isobe; Yasutoshi Kimura; Takashi Matsuno; Akihiro Nui; Koichi Hirata
Background. Recently, a novel inhibitor of inducible nitric oxide synthase, ONO-1714, was developed. We evaluated the effect of ONO-1714 on a critical warm I/R model of the pig liver. Methods. Pigs were subjected to 180 min of hepatic warm I/R under the extracorporeal circulation. We investigated the time course of changes in the serum NO2− + NO3− (NOx), the cellular distribution of endothelial and inducible nitric oxide synthase, thrombocyte-thrombi, and nitrotyrosine by immunohistochemistry. The hepatic tissue blood flow (HTBF) was measured continuously using a laser-Doppler blood flowmeter. Results. ONO-1714 at 0.05 mg/kg improved the survival rate from 54 (control group) to 100%. The serum NOx levels in the ONO-1714 group were significantly lower than those in the control group at 1, 1.5, 2, 3, and 6 hr after reperfusion. The serum aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) levels of the ONO-1714 group were significantly lower than the control group, and the HTBF of the ONO-1714 group was significantly higher than the control group. The formation of thrombocyte-thrombi and nitrotyrosine after reperfusion was significantly lower in the ONO-1714 group. Conclusions. These results indicated that ONO-1714 improved the survival rates and attenuated I/R injury in a critical hepatic warm I/R model of the pig. ONO-1714 will be beneficial for hepatectomy or liver transplantation in the clinical field.
Journal of Surgical Research | 2003
Hitoshi Kimura; Tadashi Katsuramaki; Masato Isobe; Minoru Nagayama; Makoto Meguro; Kazuma Kukita; Akihiro Nui; Koichi Hirata
BACKGROUND Previously, we clarified the role of inducible nitric oxide synthase (iNOS) and the protective effect of an iNOS inhibitor in warm ischemia and reperfusion model. In this study, we investigated whether the same effects would be obtained by iNOS inhibitor in liver transplantation model. MATERIAL AND METHODS Orthotopic liver transplantation was performed in pigs in the usual manner after about 6 h of cold preservation in University of Wisconsin solution. Aminoguanidine hemisulfate (AG) was used as the iNOS inhibitor and AG was administered intraportally at the dose of 10 mg/kg just after reperfusion. Two experimental groups were subjected, control group (n = 10), and AG group (n = 10). We investigated changes of serum nitrite/nitrate (NOx) and aspartate aminotransferase (AST). Expression of iNOS was examined by immunohistochemistry, including a double immunofluorescnce technique in combination with cofocal laser scanning microscopy. RESULTS Serum NOx and AST were significantly lower in the AG group. Histological hepatic damage and thrombocyte thrombi were attenuated in the AG group. Expression of iNOS was recognized strongly at Kupffer cells and neutrophils in the centrilobular region of liver after reperfusion by cofocal laser scanning microscopy. Moreover, iNOS staining was attenuated in AG group compared with control group. CONCLUSIONS These results indicate that hepatic ischemia and reperfusion injury in liver transplantation might be triggered by iNOS expression of Kupffer cells and neutrophils, and attenuated by administration of an iNOS inhibitor. Moreover, AG showed down regulation of iNOS expression after reperfusion.
Transplantation | 2003
Makoto Meguro; Tadashi Katsuramaki; Hitoshi Kimura; Masato Isobe; Minoru Nagayama; Kazuma Kukita; Akihiro Nui; Koichi Hirata
Background. It is still controversial whether a major mode of cell death during hepatic ischemia-reperfusion (I/R) injuries is apoptosis or necrosis. Moreover, the correlation between these cell deaths and the effects of a novel inducible nitric oxide synthase inhibitor (ONO-1714) has not been studied before. Methods. Pigs were subjected to 180 min of hepatic warm I/R under extracorporeal circulation. The control group was not administered ONO-1714. In the ONO-1714 group, ONO-1714 was administered 5 min before ischemia at a dose of 0.05 mg/kg through a portal vein catheter. The apoptotic and necrotic changes after reperfusion were examined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and hematoxylin-eosin staining. Nitrotyrosine, active caspase-3, and cytochrome c were examined by immunohistochemistry. The plasma NO2- + NO3-, aspartate aminotransferase, and lactate dehydrogenase levels were also examined. Results. In the control group, the frequency of apoptotic cells was only 2.6%; nevertheless, that of necrotic cells was 37% at 24 hr after reperfusion. ONO-1714 significantly attenuated apoptosis and necrosis, the expression of nitrotyrosine, and the increases of the plasma aspartate aminotransferase, lactate dehydrogenase, and NO2- + NO3- levels in the reperfusion phase. Conclusions. A major mode of cell death during hepatic warm I/R injury was necrosis, and apoptosis was not dominant. These necrotic changes were caused by the excess production of peroxynitrite, and ONO-1714 greatly attenuated I/R injuries as the result of inhibition of the peroxynitrite production.
Surgery Today | 2000
Tadashi Katsuramaki; Hitoshi Kimura; Masato Isobe; Minoru Nagayama; Makoto Meguro; Akihiro Nui; Takashi Matsuno; Hideki Ura; Mitsuhiro Mukaiya; Koichi Hirata
Abstract: To clarify the changes that occur in hepatic venous oxygen saturation (Shvo 2 ) during hepatic ischemia/reperfusion (I/R) injury, we examined the relationship between Shvo 2 , hepatic tissue blood flow (HTBF), and portal vein pressure (PVP) in a warm I/R model using pig livers. Female pigs weighing 18–23 kg were subjected to warm I/R under extracorporeal circulation between the superior mesentric vein and the left jugular vein to avoid portal congestion. The warm ischemic times were 120 min ( n = 4), 180 min ( n = 14), and 240 min ( n = 4). Shvo 2 , HTBF, and PVP were measured after reperfusion. The survival rates of the pigs 3 days after reperfusion were 100% in the 120-min group, 57% in the 180-min group, and 25% in the 240-min group. In the 180-min group, the Shvo 2 was lower in the pigs that died than in those that survived. There was a significant correlation between Shvo 2 and both PVP and HTBF after reperfusion. Histological examination revealed findings of severe I/R injury in pigs with a low Shvo 2 , and mild I/R injury in pigs with a stable Shvo 2 . These observations suggest that the changes in Shvo 2 could reflect the degree of hepatic I/R injury, especially that related to microcirculatory disturbances occurring at the sinusoid levels.
International Journal of Artificial Organs | 2003
Akihiro Nui; Tadashi Katsuramaki; Hitoshi Kikuchi; Kazuma Kukita; Minoru Nagayama; Makoto Meguro; Hitoshi Kimura; Masato Isobe; Koichi Hirata
We tried to make an ex vivo functioning liver with an artificial perfusate that consisted of artificial blood in the pig liver. A liver graft from a female pig weighing 20 kg was harvested in the usual manner. The perfusion solution consisted of artificial blood, L-15 medium, distilled water, bovine serum albumin, NaHCO3, NaOH, KCl, human regular insulin, 50% glucose solution, and dexamethasone. The isolated liver was perfused with this oxygenated perfusate through the portal vein at a rate of 300 ml/min for 9 hours. Seven livers were perfused for 9 hours in this system. Five of the livers showed mean oxygen consumption of over 8 ml-O2/min during perfusion. Histological findings showed that the hepatic architecture was almost completely preserved and numerous hepatocytes exhibited PAS-positive cytoplasmic glycogen deposits in these livers. These observations indicate that we have succeeded in developing an ex vivo functioning liver with an artificial perfusate employing artificial blood.
Clinical Pediatric Endocrinology | 2018
Takako Takeuchi; Yuko Yoto; Akira Ishii; Takeshi Tsugawa; Masaki Yamamoto; Tsukasa Hori; Hotaka Kamasaki; Kazutaka Nogami; Takanori Oda; Akihiro Nui; Sachiko Kimura; Takuya Yamagishi; Keiko Homma; Tomonobu Hasegawa; Maki Fukami; Yoko Watanabe; Hidehiko Sasamoto; Hiroyuki Tsutsumi
Abstract. We present a 4-yr-old boy with adrenocortical carcinoma (ACC), diagnosed due to the appearance of gynecomastia as the presenting symptom. Six months prior to admission, an acute growth spurt along with the development of bilateral breast swelling was observed. He did not present any features of virilization, including enlargement of the testes, increase in testis volume, and penis size. Laboratory investigations showed gonadotropin-independent hypergonadism, with low LH/ FSH levels and elevated estradiol/testosterone levels. Abdominal computed tomography revealed a large heterogeneous mass adjacent to the right kidney and below the liver. Pathological investigations of the biopsy specimen demonstrated that the tumor was an ACC. Pre- and post-operative combination chemotherapy with mitotane was administered and surgical resection was carried out. Post-surgery, the elevated estradiol/testosterone concentrations reverted to within the reference range. Urinary steroid profile and tissue concentration analysis of estradiol and testosterone indicated the presence of estrogen in the ACC tissue. An investigation for TP53 gene aberrations revealed the presence of a germline point mutation in exon 4 (c.215C>G (p.Pro72Arg)). In ACC, the most common symptom is virilization, and feminization, characterized by gynecomastia, is very rare. However, a diagnostic possibility of ACC should be considered when we encounter patients who have developed gynecomastia without the influence of causative factors such as obesity or puberty, and do not present with the typical signs of virilization.
Journal of Pediatric Hematology Oncology | 2006
Masaki Yamamoto; Nobuhiro Suzuki; Naoki Hatakeyama; Nobuo Mizue; Tsukasa Hori; Yuki Kuroiwa; Masato Hareyama; Takanori Oda; Tooru Kudoh; Akihiro Nui; Takashi Matsuno; Toshinori Hirama; Shigeaki Yokoyama; Jeffrey S. Dome; Hiroyuki Tsutsumi
Journal of Surgical Research | 2002
Minoru Nagayama; Tadashi Katsuramaki; Hitoshi Kimura; Masato Isobe; Makoto Meguro; Takashi Matsuno; Akihiro Nui; Koichi Hirata
Journal of Surgical Research | 2006
Akihiro Nui; Tadashi Katsuramaki; Hitoshi Kikuchi; Kazuma Kukita; Hitoshi Kimura; Makoto Meguro; Minoru Nagayama; Masato Isobe; Koichi Hirata
Transplantation Proceedings | 2000
Tadashi Katsuramaki; Masato Isobe; Hitoshi Kimura; Minoru Nagayama; Makoto Meguro; Akihiro Nui; Takashi Matsuno; Hideki Ura; Mitsuhiro Mukaiya; Koichi Hirata